Amylin Pharmaceuticals, Inc. and BioCon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid Program will Focus on the Potential Treatment of Diabetes
SAN DIEGO and BANGALORE, India, Sept. 10 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (Nasdaq: AMLN) and Biocon, Limited (NSE: BIOCON)
announced today that they have entered into an exclusive agreement to jointly
develop, commercialize and manufacture a novel peptide therapeutic for the
potential treatment of diabetes. Amylin and Biocon will collaborate to develop
the therapeutic potential of the compound and share development costs.
Research will center on Amylin's "phybrid" technology. A phybrid is a peptide
hybrid molecule that combines the pharmacological effects of two peptide
hormones into a single molecular entity.